- Company
- Daewoong-Merck pursues full-cycle AI-based new drug dev
- by Lee, Seok-Jun Nov 1, 2023 05:40am
- Daewoong Pharmaceutical announced on the 31st that it had signed a memorandum of understanding (MOU) with Merck Life Science for the ‘establishment of an AI-based new drug development platform and full-cycle technical support of new drug development.’ The companies will work together to improve the efficiency and productivity of the ne
- Company
- 5th JAK inhibitor released…heats up competition
- by Kim, Jin-Gu Nov 1, 2023 05:40am
- The fifth product was released in the market for JAK inhibitors, an oral autoimmune disease treatment drug. The JAK inhibitor market, which has continued rapid growth recently, is expected to grow more rapidly due to the addition of the new product. Competition among products is also expected to intensify. While Olumiant (baricitinib),
- Company
- Gilead aims for reimbursement of COVID-19 tx Veklury
- by Eo, Yun-Ho Nov 1, 2023 05:40am
- COVID-19 treatment Veklury is aiming to be listed on insurance benefits. According to related industry sources, Gilead Sciences Korea submitted an application for Veklury's benefit last month. As with Pfizer Korea's Paxlovid, the government plans to end the current free support system from the first half of next year, so it is believed that
- Company
- Global biosimilar market worth KRW 3.9 tril…Pfizer vs Amgen
- by Kim, Jin-Gu Oct 31, 2023 05:35am
- Prospects of the global biosimilar market have shown that the global biosimilar market, which is currently worth USD 28.62 billion (about KRW 39 trillion), will expand rapidly to reach USD 76.51 billion (about KRW 102 trillion) by 2028. On the 30th, the Korea Biotechnology Industry Organization made the forecast, citing biosimilar market data
- Company
- Public opinion grows on if PO kidney tx should be covered
- by Nho, Byung Chul Oct 31, 2023 05:35am
- As first-in classes related to kidney disease are blocked by insurance registration review barriers, it seems urgent to improve the system through social consensus. A drug related to this is Kerendia, Bayer's chronic renal failure treatment that was newly introduced for the first time in 20 years. Renal anemia that occurs due to abnormal
- Company
- Zavicefta nears final negotiations for reimb in KOR
- by Eo, Yun-Ho Oct 31, 2023 05:35am
- Whether the next-generation antibiotic ‘Zavicefta’ will be successfully listed for reimbursement is gaining attention. Under the Ministry of Health and Welfare’s order to proceed to drug pricing negotiations, Pfizer Korea is soon set to begin pricing discussions for ‘Zavicefta’ (ceftazidime-avibactam). The drug passed the Health Insu
- Company
- Jyseleca to be launched in earnest next month
- by Eo, Yun-Ho Oct 30, 2023 05:30am
- A fifth entrant has joined the competition in the JAK inhibitor market. The Japanese pharmaceutical company, Eisai Korea’s ‘Jyseleca’ will be listed for reimbursement starting next month (November). Its first reimbursed indication is rheumatoid arthritis and moderate to severe active rheumatoid arthritis. Patients eligible for reimburs
- Company
- Heart failure drug Entresto continues to grow rapidly
- by Kim, Jin-Gu Oct 30, 2023 05:30am
- Novartis' heart failure treatment Entresto continues to grow rapidly thanks to increased benefits. Although it has been six years since it was launched in Korea, prescriptions are increasing by more than 30% every quarter compared to last year. However, Entresto faces challenges from several successor products. Recently, Verquvo, a new heart
- Company
- Nic Horridge resigns as CEO of Roche Korea
- by Eo, Yun-Ho Oct 30, 2023 05:29am
- According to related industries, CEO Nic Horridge will step down as CEO of Roche's Korean subsidiary at the end of this month and become CEO of the Australian subsidiary. CEO Nic Horridge was appointed as CEO of Roche Korea in October 2018 and led the company for approximately five years. During his tenure, he achieved the expansion of pr
- Company
- Nephoxil can be prescribed at general hospitals
- by Eo, Yun-Ho Oct 27, 2023 05:33am
- Nephoxil, a hyperphosphatemia treatment drug, is entering the prescription range of general hospitals. According to related industries, Kyowa Kirin Korea's Nepocsil has passed the Drug Committee of about 50 hospitals across the country, including Sinchon Severance Hospital. Nephoxil was developed as a new iron-based phosphorus binder with hi
